

ASX ANNOUNCEMENT

Appendix 4C – Quarterly Cash Flow Report

Highlights for the quarter ended 30 June 2016:

- **Cash outflow reduced by \$824k on previous quarter**
- **INOV8 additional \$500k placement**
- **FDA Over-the-Counter clearance for PeriCoach**
- **AutoStart Burette granted US patent**

28th June 2016: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® System, is pleased to announce its Appendix 4C - Quarterly cash flow report for period ending 30 June 2016.

Analytica's cost reduction measures have resulted in cash outflow of \$881k for the quarter a reduction of \$824k on the previous quarter. A share purchase plan and share placements in April increased capital by \$2,105k. The company estimates a tax incentive R&D refund of approximately \$1.3m next quarter. American Virgin Islands cornerstone investor INOV8 LLC has committed to further placements of \$250k at the end of August and a further \$250k at the end of September. This additional \$500k in 2 tracts together with the cost reduction program extends Analytica's cash well into the next calendar year. The loan facility of \$400k from Chairman Dr Michael Monsour continues to be available.

Version 3 of the PeriCoach system has reached production and Analytica prepares to gather verification and validation data for this next gen device. Software development is on track as enhancements to the database are near completion and new features to the app, such as the Bladder Diary have been introduced. These user interface updates provide users with a comprehensive picture of treatment progress which motivates them to stay engaged. Compliance with the exercise programme is key to achieving positive results for pelvic floor exercise.

With FDA granting clearance, the PeriCoach System is a medical device with internationally accepted safety testing, supported by clinical papers and case studies and no longer requires a prescription. Analytica aims to ensure that the company's commercialisation partner has a reduced time to market and support from the clinical community. This quarter, additional clinical papers and testimonials were collected along with case studies published in the peer reviewed Urologic Nursing Journal of the US Society of Urologic Nurses and Associates.

Analytica achieved a significant milestone this quarter after being granted patent protection for its AutoStart® burette. Obtaining this patent is another important step in the commercialisation of the AutoStart infusion system. The patent increases the market opportunity within the US and positions the company for additional license deals for the product.

Also in this period Analytica's Australian partner, Medical Australia Ltd (ASX: MLA) also succeeded in having the AutoStart infusion system added to the Queensland Health tender list under their Tuta FirstFlow brand name. This



permits any Queensland hospital or health clinic to buy the product.

“Reaching the US FDA over the counter clearance, launching new app features, garnering further clinical support and published evidence for PeriCoach in the first half of 2016 demonstrates our commitment to put Analytica in the best possible position for a partnership,” said Geoff Daly, CEO of Analytica. “The continued investment by our cornerstone investor INOV8 reflects confidence in our strategic direction.”

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica’s lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale from pericoach.com in Australia and New Zealand, UK and Ireland, and in the USA.



Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

30/6/2016

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (12 months) \$A'000
1.1 Receipts from customers	15	191
1.2 Payments for		
(a) staff costs	(318)	(1,382)
(b) advertising and marketing	(186)	(2,056)
(c) research and development	(296)	(1,547)
(d) leased assets	-	-
(e) other working capital	(95)	(1,132)
(f) realised currency gains	(4)	(49)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	4	21
1.5 Interest and other costs of finance paid	-	(2)
1.6 Income taxes paid	-	-
1.7 Other-		
(a) Net sales income	-	-
(b) R & D Tax Concession		1,894
(c) Royalty Income		7
(d) Other Grant Income		-
Net operating cash flows	(880)	(4,055)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

		Current quarter \$A'000	Year to date (12 months) \$A'000
1.8	Net operating cash flows (carried forward)	(880)	(4,055)
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(1)	(11)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (purchase of Convertible Notes)	-	-
	Net investing cash flows	(1)	(11)
1.14	Total operating and investing cash flows	(881)	(4,066)
Cash flows related to financing activities			
1.15	Proceeds from issues of shares	2,105	5,235
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings:	-	-
1.19	Dividends paid	-	-
1.20	Other Creditors (costs of fund raising)	(115)	(469)
	Net financing cash flows	1,990	4,766
	Net increase (decrease) in cash held	1,109	700
1.21	Cash at beginning of quarter/year to date	145	554
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	Cash at end of quarter	1,254	1,254

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	133
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Payment of director's fees and compulsory superannuation.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	400	0
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1,254	145
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	1,254	145

Acquisitions and disposals of business entities

	Acquisitions	Disposals
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:

Date: 28th July 2016

Print name: Ross Mangelsdorf

+ See chapter 19 for defined terms.